β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies.
Age Factors
Aged
Aged, 80 and over
Amyloid beta-Peptides
/ cerebrospinal fluid
Apolipoprotein E4
/ genetics
Biomarkers
/ metabolism
Cognitive Dysfunction
/ etiology
Cohort Studies
Female
Humans
Lewy Body Disease
/ classification
Male
Middle Aged
Peptide Fragments
/ cerebrospinal fluid
Phenotype
Positron-Emission Tomography
tau Proteins
/ cerebrospinal fluid
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
12
02
2020
accepted:
06
08
2020
pubmed:
30
9
2020
medline:
26
1
2021
entrez:
29
9
2020
Statut:
ppublish
Résumé
In a multicenter cohort of probable dementia with Lewy bodies (DLB), we tested the hypothesis that β-amyloid and tau biomarker positivity increases with age, which is modified by We included 417 patients with DLB (age 45-93 years, 31% women). Positivity on β-amyloid (A+) and tau (T+) biomarkers was determined by CSF β-amyloid A-T- was the largest group (39%), followed by A+T- (32%), A+T+ (15%), and A-T+ (13%). The percentage of A-T- decreased with age, and A+ and T+ increased with age in both women and men. A+ increased more in Alzheimer disease pathologic changes are common in DLB and are associated with the clinical phenotype. β-Amyloid is associated with cognitive impairment, and tau pathology is associated with lower frequency of clinical features of DLB. These findings have important implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB. This study provides Class II evidence that in patients with probable DLB, β-amyloid is associated with lower cognitive performance and tau pathology is associated with lower frequency of clinical features of DLB.
Identifiants
pubmed: 32989106
pii: WNL.0000000000010943
doi: 10.1212/WNL.0000000000010943
pmc: PMC7836666
doi:
Substances chimiques
Amyloid beta-Peptides
0
Apolipoprotein E4
0
Biomarkers
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
tau Proteins
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3257-e3268Subventions
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : R37 AG011378
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG041851
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR018898
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG040042
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States
Organisme : NINDS NIH HHS
ID : U01 NS100620
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG011378
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS080820
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 American Academy of Neurology.
Références
Acta Neuropathol. 2015 May;129(5):729-48
pubmed: 25758940
J Alzheimers Dis. 2018;61(1):169-183
pubmed: 29171991
JAMA Neurol. 2016 Nov 1;73(11):1334-1341
pubmed: 27654968
Ann Neurol. 2017 Jan;81(1):58-67
pubmed: 27863444
JAMA Neurol. 2020 Apr 1;77(4):508-516
pubmed: 31961372
Mov Disord. 2018 Feb;33(2):262-272
pubmed: 29168583
Brain. 2016 Oct;139(Pt 10):2740-2750
pubmed: 27452602
Lancet Neurol. 2017 Jan;16(1):55-65
pubmed: 27979356
J Neural Transm (Vienna). 2016 Apr;123(4):431-8
pubmed: 26852137
Neurology. 2012 Jan 3;78(1):47-54
pubmed: 22170879
Neurology. 2014 Aug 26;83(9):801-9
pubmed: 25056580
Biol Psychiatry. 2008 Nov 15;64(10):850-5
pubmed: 18395699
J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):109-110
pubmed: 31366604
Acta Neuropathol. 2010 Apr;119(4):421-33
pubmed: 20204386
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Dement Geriatr Cogn Disord. 2009;28(4):314-9
pubmed: 19844105
Alzheimers Dement. 2018 Nov;14(11):1470-1481
pubmed: 29499171
Mov Disord. 2012 Jul;27(8):965-73
pubmed: 22693110
Neurology. 2015 Feb 3;84(5):496-9
pubmed: 25552579
Alzheimers Dement. 2019 Mar;15(3):400-409
pubmed: 30439333
J Alzheimers Dis Parkinsonism. 2018;8(4):
pubmed: 30473927
J Alzheimers Dis. 2010;22(1):87-95
pubmed: 20847452
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):113-118
pubmed: 27794030
J Alzheimers Dis. 2017;57(3):787-795
pubmed: 28304294
J Alzheimers Dis. 2016 Aug 18;54(1):287-95
pubmed: 27567832
Brain. 2019 Oct 1;142(10):3230-3242
pubmed: 31501889
Brain. 2008 Mar;131(Pt 3):665-80
pubmed: 18263627
Neurology. 2018 Sep 18;91(12):e1182-e1195
pubmed: 30143564
J Neural Transm (Vienna). 2018 Apr;125(4):615-650
pubmed: 29222591
J Alzheimers Dis. 2016;51(4):1069-83
pubmed: 26923009
Neurobiol Aging. 2018 Nov;71:171-178
pubmed: 30149288
Neurology. 2020 Jan 21;94(3):e282-e291
pubmed: 31862783
J Nucl Med. 2009 Jun;50(6):878-86
pubmed: 19443597
Neurobiol Aging. 2012 Sep;33(9):2091-105
pubmed: 22018896
Neurology. 2003 May 27;60(10):1586-90
pubmed: 12771246
Alzheimers Dement. 2018 Mar;14(3):330-339
pubmed: 29100980
Neurology. 2005 Dec 27;65(12):1863-72
pubmed: 16237129
Int Psychogeriatr. 2013 Nov;25(11):1839-48
pubmed: 23919950
Neurodegener Dis Manag. 2019 Oct;9(5):247-250
pubmed: 31580225
Mol Psychiatry. 2019 Aug;24(8):1112-1134
pubmed: 30635637
Acta Neuropathol Commun. 2013 Oct 09;1:65
pubmed: 24252435
Mov Disord. 2016 Aug;31(8):1203-8
pubmed: 27296778
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494